NCT05057702: PNOC027

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

Recruiting now NA Last updated 15 April 2026

What this trial tests

NA trial testing Specialized Tumor Board Treatment Plan in Medulloblastoma in 74 participants. Currently enrolling.

Timeline

22 February 2022

Primary endpoint
31 December 2027

31 January 2028

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	other
Enrollment	74
Start date	22 February 2022
Primary completion	31 December 2027
Estimated completion	31 January 2028
Sites	8 locations across United States

Drugs / interventions tested

• Specialized Tumor Board Treatment Plan
• Combinations — full drug profile →

Conditions studied

• Medulloblastoma — all drugs for Medulloblastoma →
• Medulloblastoma, Childhood — all drugs for Medulloblastoma, Childhood →
• Medulloblastoma Recurrent — all drugs for Medulloblastoma Recurrent →
• Ependymoma — all drugs for Ependymoma →

Sponsor

University of California, San Francisco

Who can join

Adults 12 Months to 39, any sex, with Medulloblastoma or Medulloblastoma, Childhood. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group.
   Cooney T, Lindsay H, Leary S, Wechsler-Reya R. · · 2023 · cited 19× · PMID 36516489 · DOI 10.1016/j.neo.2022.100861
2. Mechanistic insights into medulloblastoma relapse.
   Peterson K, Turos-Cabal M, Salvador AD, Palomo-Caturla I, et al · · 2024 · cited 6× · PMID 38857789 · DOI 10.1016/j.pharmthera.2024.108673
3. Current Strategies for Management of Medulloblastoma.
   Prados MD. · · 2023 · cited 5× · PMID 37627881 · DOI 10.3390/diagnostics13162622
4. Targeted therapy in pediatric central nervous system tumors: a review from the National Pediatric Cancer Foundation.
   Siegel BI, Patil P, Prakash A, Klawinski DM, et al · · 2025 · cited 3× · PMID 40094009 · DOI 10.3389/fonc.2025.1504803
5. Effective re-induction regimen for children with recurrent medulloblastoma.
   O'Halloran K, Phadnis S, Friedman GK, Metrock K, et al · · 2024 · cited 2× · PMID 38863988 · DOI 10.1093/noajnl/vdae070
6. Case Report: Application of <i>ex-vivo</i> drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.
   Tan PK, Martins TJ, Becker PS, Wechsler-Reya RJ, et al · · 2025 · cited 1× · PMID 40852486 · DOI 10.3389/fonc.2025.1606575
7. Treatment strategies for relapsed medulloblastoma in the pediatric population: illustrative case.
   Lockhart Z, Ruiz VY, King Z, Kirnaz S, et al · · 2026 · PMID 41871404 · DOI 10.3171/case25612
8. Informing development of brain cancer therapies within "preclinical trials" using ex vivo patient tumors.
   Adefolaju A, Kram DE, Mann B, Hingtgen S, et al · · 2026 · PMID 41270976 · DOI 10.1016/j.addr.2025.115736